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Haufen+(n¼4) Haufen- (n¼9) p-value*
Peak BKV
after HCT
(copies/mL)
1,255,140
[144,512-1,900,000,000]
1,173,953
[1537-6,000,000]
0.44
Hemorrhagic
cystitis
3 (75%) 6 (67%) 1.00
Dialysis 3 (75%) 0 (0%) 0.01
Death 3 (75%) 2 (22%) 0.22
Data shown as median [IQR] or n (%).
*Wilcoxon rank-sum or Fisher’s exact. Urine samples from 2/15 tested
subjects could not be evaluated.
Figure 1. By routine electron microscopy, a large polyomavirus Haufen cast is
detected in the urine of a hematopoietic cell transplant recipient.
Figure 2. Kidney autopsy specimen from a hematopoietic cell transplant
recipient with detectable urine Haufen. Tissue stained for BK virus using DNA
in situ hybridization. Although the tissue is autolyzed, kidney tubules (arrow
head) and tubular lumens (arrow) show positive staining for BK virus infected
cells,deﬁning polyomavirus nephropathy.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S231detected in 4/15 subjects (27%; 5/20 urine samples),
including one subject with autopsy conﬁrmed PVN (Fig 2).
The table shows associations between urinary PV-Haufen,
peak BKV, and clinical outcomes after HCT.
Conclusions: We provide pilot data potentially indicating a
high risk of PVN after HCT. PV-Haufen were associated with
kidney injury requiring renal replacement therapy and may
thus serve as a non-invasive test to identify patients with
BKV who are at high risk for PVN. More research is needed
including longitudinal follow-up, careful monitoring of renalfunction, and correlation of urinary PV-Haufen data with
BKV and tissue ﬁndings, when available.311
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No prospective or retrospective studies have aimed to
determine the utility, appropriate timing, or health care
utilization (HCU) associated with routine bone marrow (BM)
and cerebrospinal ﬂuid (CSF) analysis following AlloHCT in
children with leukemia.
We conducted a national survey of 62 pediatric bone
marrow transplant practitioners regarding their use of
routine BM/CSF analysis post-AlloHCT. For acute lympho-
blastic leukemia (ALL) patients, 41 physicians (66%) re-
ported performing routine BM analysis in all such patients;
15 (24%) in some patients; and 6 (10%) in no patients. For
acute myeloid leukemia (AML), 39 (63%) reported doing so
in all patients; 9 (14%) in some patients; and 14 (23%) in no
patients.
No standard exists dictating the proper timing or frequency
of screening. For ALL, 11 physicians (24%) reported per-
forming one BM biopsy in the ﬁrst year, 11 (24%) perform
two, 6 (13%) perform three, 12 (27%) perform four, and 5
(12%) perform 5-10. The most common time points to
perform such screening were day 90-100 and day 365. Data
were similar for AML.
The practice of performing routine CSF analysis is even more
varied. Eleven physicians (18%) reported doing so in all post-
AlloHCT ALL patients; 28 (45%) in no such patients; and 23
(37%) only in previously CNS-positive patients. In AML pa-
tients, most practitioners do not perform routine CSF anal-
ysis. Routine usage of intra-thecal chemotherapy is variable
as well.
We also performed a retrospective chart review of 108 pa-
tients who underwent BM/CSF analysis at routine intervals
following AlloHCT at our center. There were 41 relapses with
a median time to relapse of 171 days. Five of these relapses
occurred after day 365. Of the 41 relapses, 11 (27%) were
identiﬁed by routine screening procedures (10 by BM, 1 by
CSF). All relapses identiﬁed by routine surveillance were
detected before day 365.
Thirty-eight patients had routine day 365 BM analyses; zero
of 38 had evidence of relapse. Of these,13 had ALL and 25 had
AML (median age 11 years); median WBC count was 5.8 x
109/L (range 1.8 to 15.6); median platelet count was 173 x
109/L (range 36 to 424); mean peripheral blood chimerism
was 96.9% donor.
With the ultimate goal of reducing HCU, we analyzed pro-
cedure charges and time data. Median charges associated
with routine BM/CSF analysis amounted to $6,613. Median
time spent by families and physicians in the procedure suite
was 3 hours and 34 minutes, respectively.
This data conﬁrms a lack of consensus regarding routine BM/
CSF relapse surveillance following AlloHCT in children with
leukemia. We documented a questionable yield from this
surveillance with an associated high health care utilization.
Therefore, the utility of these routine procedures at day 365
may not be sufﬁciently high to justify their continued routine
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centers may help to provide conclusive evidence.312
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Alemtuzumab, ﬂudarabine, and melphalan reduced intensity
conditioning regimens are increasingly used for the he-
matopoietic cell transplantation of pediatric and young adult
patients with non-malignant diseases. Data regarding large
patient groups are limited. We retrospectively analyzed the
outcomes of 206 patients with primary immunodeﬁciencies,
metabolic diseases, and non-fanconi anemia marrow failure
disorders who underwent 210 RIC HCT procedures at Cin-
cinnati Children’s Hospital. Ninety-seven percent of patients
engrafted. Mixed donor and recipient chimerism developed
in 46% of patients. The risk was highest in patients who
received proximal or higher dose/kg alemtuzumab schedules
(all HR>2, all p<0.05) or cord blood grafts (HR 3.122, CI
1.236-7.888, p¼ 0.016). Patients with marrow failure were
protected against mixed chimerism (HR 0.208, CI 0.061-
0.709, p¼0.012). The overall cumulative incidences of grades
II-IV and III-IV acute GHVDwere 25% (CI 20-32%) and 18% (CI
14%-25%). Five percent of patients required re-trans-
plantation. One-year survival without re-transplantationwas
75% (CI 69-81%). Only 2 deaths were related to acute toxic-
ities; themajority were related to infections. Age, HLAmatch,
and grades III-IV acute GVHD impacted survival. Despite the
high incidence of mixed chimerism, alemtuzumab, ﬂudar-
abine, and melphalan RIC HCT offers minimal life-threat-
ening acute toxicities and good outcomes for many patients.313
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reduced intensity conditioning (RIC) regimens are increas-
ingly used for pediatric patients with non-malignant dis-
eases. We have previously reported that the incidences of
acute graft versus host disease (GVHD) andmixed chimerism
are both inﬂuenced by the timing and dose of alemtuzumab.
We speculated that these effects were due to variations in
peri-transplant levels of alemtuzumab and resultant differ-
ences in extent of graft T cell depletion.
Hypothesis: We hypothesized that low or absent levels of
alemtuzumab would result in elevated risk for acute GVHD
but low risk of mixed chimerism, and that high levels of
alemtuzumab would result in low risk of acute GVHD but
increased risk of mixed chimerism.
Methods: We measured alemtuzumab levels on the day of
graft infusion +/- 3 days in 90 patients who received an
alemtuzumab, ﬂudarabine, and melphalan RIC regimen. We
created cumulative incidence curves to compare the in-
cidences of acute GVHD grades II-IV and mixed chimerism in
patients with alemtuzumab levels of 0.1mg/mL or less versus
0.2mg/mL or greater. We used cause-speciﬁc Cox hazard
regression to model the risks of acute grades II-IV GVHD or
mixed chimerism (deﬁned as whole blood donor chimerism
of less than 95% on two or more consecutive occasions)
taking into account the covariates of age, diagnosis, HLA
Match, graft source, and alemtuzumab level (mg/mL,
continuous variable). All computations were done using R
(The R Foundation for Statistical Computing, Vienna,
Austria). Final models were selected using stepwise selec-
tion. Statistical signiﬁcance was considered for p<0.05.
Results: The cumulative incidence of acute GVHD grades II-
IV was 48% in patients with alemtuzumab levels of 0.1 mg/mL
or less, and 18% in patients with levels of 0.2mg/mL or greater
(p<0.001). The cumulative incidence of mixed chimerism
was 34% in patients with alemtuzumab levels of 0.1 mg/mL or
less, and 48% in patients with levels of 0.2mg/mL or greater
(p¼0.24). In multivariate analysis, we found that alemtuzu-
mab level was the only signiﬁcant factor associated with the
risks of acute grades II-IV GVHD and mixed chimerism.
Increasing levels of alemtuzumab decreased the risk of
grades II-IV acute GVHD (HR 0.495, CI 0.282-0.867, p¼0.014).
Conversely, increasing levels of alemtuzumab increased the
risk of mixed chimerism (HR 1.169, CI 1.033-1.324, p¼0.014).
Receipt of a cord blood graft also inﬂuenced the risk (HR
4.134, p¼0.068) but did not reach statistical signiﬁcance,
perhaps due to small sample size.
Conclusion: We conclude that peri-transplant levels of
alemtuzumab dictate the risks for acute GVHD and mixed
chimerism. Detailed pharmacokinetic studies are needed to
optimize and individualize alemtuzumab dosing for pediat-
ric patients in order to minimize these complications.314
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Background: Myeloablative conditioning regimens used for
hematopoietic stem cell transplant (HSCT) are known to
affect endocrine function, most commonly causing primary
